# A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers

> **NCT06672900** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Aligos Therapeutics** · enrollment: 24 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** Carbamazepine
- **DRUG:** Itraconazole (Sporanox)
- **DRUG:** ALG-000184

## Key facts

- **NCT ID:** NCT06672900
- **Lead sponsor:** Aligos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-09
- **Primary completion:** 2025-07-07
- **Final completion:** 2025-07-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06672900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06672900, "A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT06672900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*